BioSpace News Archive

Business

Biotech Movers and Shakers for July 16

With the Independence Day holiday in the rearview mirror, numerous biopharma companies continued to adjust their leadership ranks and strengthen the members of various boards representing and overseeing the companies.

July 16, 2018
·
5 min read
·
Alex Keown
Biotech Bay

Pliant Therapeutics Snags $62 Million

Two months after unveiling a new approach to identify novel biomarkers for the detection and treatment of idiopathic pulmonary fibrosis, South San Francisco-based Pliant Therapeutics secured $62 million in a Series B financing round to support its research programs.

July 16, 2018
·
2 min read
·
Alex Keown
Drug Development

Astellas and Pfizer Win New Prostate Cancer Indication From the FDA for Xtandi

Four months after filing a supplemental New Drug Application with the U.S. Food and Drug Administration, Astellas and Pfizer snagged regulatory approval for Xtandi as a treatment for non-metastatic Castration-Resistant Prostate Cancer (CRPC).

July 16, 2018
·
2 min read
·
Alex Keown
Policy

FDA Warns Online Drug Consumers of Fake Scam Letters

The U.S. Food and Drug Administration (FDA) is warning consumers who seek to buy medications through websites that they may be opening themselves up to of a swarm of imposters claiming to be representatives of the regulatory agency.

July 16, 2018
·
2 min read
·
Alex Keown
FDA

June was a Busy Month for the FDA, Which Approved 7 Novel Drug Approvals

The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.

July 16, 2018
·
3 min read
·
Alex Keown
Drug Development

Ramaswamy’s Urovant, Four Other Companies, Join IPO Frenzy

One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.

July 16, 2018
·
3 min read
·
Alex Keown
Genetown

New Study Says DNA Damage From CRISPR-Cas9 Gene-Editing Has Been Underestimated

Shares of CRISPR Therapeutics (-8 percent), Editas Medicines (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects.

July 16, 2018
·
3 min read
·
Alex Keown
Biotech Bay

AI Company Verge Genomics Snags $32 Million in Series A Funding

Verge Genomics, a drug discovery company that uses artificial intelligence and machine learning to develop new therapeutics, secured $32 million in a Series A financing round to accelerate its drug discovery programs.

July 16, 2018
·
2 min read
·
Alex Keown
FDA

With Looming Bioterrorism Threats, FDA Approves First Smallpox Therapeutic

Shares of Siga Technologies soared more than 11 percent late Friday after the company announced that its smallpox treatment Tpoxx was approved by the U.S. Food and Drug Administration.

July 16, 2018
·
2 min read
·
Alex Keown
Business

Spero Teams Up with U.S. Government Agencies on Development of SPR944

Shares of Cambridge, Mass.-based Spero Therapeutics are climbing this morning after the company announced it secured up to $54 million from the government to support its development of SPR944 as a potential treatment against drug-resistant infections.

July 16, 2018
·
2 min read
·
Alex Keown